Novo Nordisk Shares Slide 8% After Obesity Drug Misses Noninferiority Target
Novo Nordisk’s Phase 3 T-202 trial of its investigational obesity drug achieved a 12% average weight loss over 72 weeks versus 15% for the rival tirzepatide, failing to meet its noninferiority margin. The results triggered an 8% drop in the company’s share price in Copenhagen trading.
1. Trial Data Falls Short
In the Phase 3 T-202 study, Novo Nordisk’s experimental GLP-1 candidate recorded a mean 12% body-weight reduction over 72 weeks, compared with 15% for the competing tirzepatide treatment, missing the predefined noninferiority threshold by three percentage points.
2. Share Price Reaction
Following disclosure of the trial outcome, Novo Nordisk’s shares plunged 8% in Copenhagen, marking the steepest one-day decline since last year, as investors recalibrated growth expectations for the obesity franchise.
3. Implications for Pipeline
The setback raises questions about timing for other obesity candidates in late-stage development and may prompt Novo Nordisk to accelerate alternate programs or seek partnerships to bolster its weight-loss portfolio.